Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 5.86B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 205.54M |
| Shares Out | 84.69M |
| EPS (ttm) | 2.41 |
| PE Ratio | 28.70 |
| Forward PE | 20.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 384,166 |
| Open | 68.66 |
| Previous Close | 69.63 |
| Day's Range | 68.20 - 69.78 |
| 52-Week Range | 42.12 - 77.40 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 77.73 (+12.2%) |
| Est. Earnings Date | Oct 27, 2021 |
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial...
Financial Performance
In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.73, which is an increase of 12.18% from the latest price.
News
Integra LifeSciences Announces Participation in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the...
Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Integra (IART) Stock for Now
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Integra's Update On FY21 Acell Revenues To Weigh On Stock, Piper Sandler Says
Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation (NASDAQ:IART) to $72 from $70 and reiterated a Neutral rating following the Q2 beat. The company posted Q2 EPS of $...
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Integra Lifesciences Q2 Earnings
Shares of Integra Lifesciences (NASDAQ:IART) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 139.39% over the past year to $0.79, which beat the esti...
Integra LifeSciences Reports Second Quarter 2021 Financial Results
Raises Full-Year 2021 Guidance Raises Full-Year 2021 Guidance
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of...
Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone
Integra's (IART) SurgiMend Gets Innovative Technology Contract
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Integra LifeSciences Receives Innovative Technology Contract from Vizient for SurgiMend® Collagen Matrix for Soft Tis...
Contract awarded for products that bring improvement to healthcare industry Contract awarded for products that bring improvement to healthcare industry
Integra LifeSciences to Host Second Quarter 2021 Financial Results Conference Call on July 28, 2021
PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2021 financial resul...
Integra LifeSciences Announces CEO Succession Plan
Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor Peter Arduini to serve as President and CEO through the end of 2021 Candidate search l...
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Integra LifeSciences Hosts Virtual Investor Day
PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...
Integra LifeSciences to Host Virtual Investor Day on May 20, 2021
PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Integra (IART) Hits Fresh High: Is There Still Room to Run?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra LifeSciences (IART) Q1 Earnings and Revenues Top Estimates
Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Integra Lifesciences: Q1 Earnings Insights
Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, whi...